CRISPR Therapeutics Gestione

Gestione criteri di controllo 3/4

CRISPR Therapeutics Il CEO è Sam Kulkarni, nominato in Dec2017, e ha un mandato di 6.92 anni. la retribuzione annua totale è $ 12.32M, composta da 5.9% di stipendio e 94.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.33% delle azioni della società, per un valore di CHF 11.61M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.1 anni e 5.4 anni.

Informazioni chiave

Sam Kulkarni

Amministratore delegato

US$12.3m

Compenso totale

Percentuale dello stipendio del CEO	5.9%
Mandato del CEO	6.9yrs
Proprietà del CEO	0.3%
Durata media del management	5.1yrs
Durata media del Consiglio di amministrazione	5.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Sam Kulkarni rispetto agli utili di CRISPR Therapeutics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$240m
Jun 30 2024	n/a	n/a	-US$266m
Mar 31 2024	n/a	n/a	-US$217m
Dec 31 2023	US$12m	US$725k	-US$154m
Sep 30 2023	n/a	n/a	-US$354m
Jun 30 2023	n/a	n/a	-US$416m
Mar 31 2023	n/a	n/a	-US$524m
Dec 31 2022	US$21m	US$700k	-US$650m
Sep 30 2022	n/a	n/a	-US$681m
Jun 30 2022	n/a	n/a	-US$633m
Mar 31 2022	n/a	n/a	US$312m
Dec 31 2021	US$17m	US$670k	US$378m
Sep 30 2021	n/a	n/a	US$412m
Jun 30 2021	n/a	n/a	US$447m
Mar 31 2021	n/a	n/a	-US$392m
Dec 31 2020	US$9m	US$625k	-US$349m
Sep 30 2020	n/a	n/a	-US$211m
Jun 30 2020	n/a	n/a	US$20m
Mar 31 2020	n/a	n/a	US$46m
Dec 31 2019	US$16m	US$550k	US$67m
Sep 30 2019	n/a	n/a	-US$11m
Jun 30 2019	n/a	n/a	-US$200m
Mar 31 2019	n/a	n/a	-US$185m
Dec 31 2018	US$10m	US$518k	-US$165m
Sep 30 2018	n/a	n/a	-US$117m
Jun 30 2018	n/a	n/a	-US$91m
Mar 31 2018	n/a	n/a	-US$75m
Dec 31 2017	US$7m	US$405k	-US$68m

Compensazione vs Mercato: La retribuzione totale di Sam ($USD 12.32M ) è superiore alla media delle aziende di dimensioni simili nel mercato Swiss ($USD 1.43M ).

Compensazione vs guadagni: La retribuzione di Sam è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Sam Kulkarni (46 yo)

6.9yrs

Mandato

US$12,322,196

Compensazione

Dr. Samarth Kulkarni, Ph D, also known as Sam, has been an Independent Director of Repare Therapeutics Inc. since November 2019. Dr. Kulkarni serves as Independent Director of Oruka Therapeutics, Inc since...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Samarth Kulkarni	CEO & Chairman	6.9yrs	US$12.32m	0.33% CHF 11.6m
Raju Prasad	Chief Financial Officer	1.7yrs	US$5.91m	0.012% CHF 411.5k
James Kasinger	General Counsel & Secretary	7.5yrs	US$3.51m	0.073% CHF 2.6m
Shaun Foy	Founder	no data	Nessun dato	Nessun dato
Emmanuelle Charpentier	Co-Founder & Scientific Advisory Board Member	no data	Nessun dato	Nessun dato
Craig Mello	Scientific Founder & Advisory Board Member	no data	Nessun dato	Nessun dato
Chad Cowan	Scientific Founder	no data	Nessun dato	Nessun dato
Matthew Porteus	Scientific Founder & Advisory Board Member	no data	Nessun dato	Nessun dato
Daniel Anderson	Scientific Founder & Advisory Board Member	no data	Nessun dato	Nessun dato
Julianne Bruno	Chief Operating Officer	less than a year	Nessun dato	0.016% CHF 569.2k
Stephen Kennedy	Head of Technical Operations	5.1yrs	Nessun dato	Nessun dato
Susan Kim	Vice President of Corporate Communications & Investor Relations	no data	Nessun dato	Nessun dato

5.1yrs

Durata media

49yo

Età media

Gestione esperta: Il team dirigenziale di 1CG è esperto e expertise (durata media dell'incarico 5.1 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Samarth Kulkarni	CEO & Chairman	6.4yrs	US$12.32m	0.33% CHF 11.6m
Emmanuelle Charpentier	Co-Founder & Scientific Advisory Board Member	no data	Nessun dato	Nessun dato
Craig Mello	Scientific Founder & Advisory Board Member	no data	Nessun dato	Nessun dato
Matthew Porteus	Scientific Founder & Advisory Board Member	no data	Nessun dato	Nessun dato
Daniel Anderson	Scientific Founder & Advisory Board Member	no data	Nessun dato	Nessun dato
Douglas Treco	Lead Independent Director	4.4yrs	US$552.56k	0.0023% CHF 82.2k
Ali Behbahani	Independent Director	9.6yrs	US$545.06k	0.00032% CHF 11.2k
Katherine High	Independent Director	5.4yrs	US$532.56k	0% CHF 0
Simeon George	Independent Director	9.6yrs	US$542.56k	0% CHF 0
Stephen Elledge	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
John Greene	Independent Director	5.4yrs	US$555.06k	0% CHF 0
H. Fleming	Independent Director	3.4yrs	US$536.24k	0% CHF 0

5.4yrs

Durata media

58yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 1CG sono considerati esperti (durata media dell'incarico 5.4 anni).

CRISPR Therapeutics Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Insufficient new directors

CRISPR Therapeutics Announces Executive Changes

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024

CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023

Insufficient new directors

Recent updates

Second quarter 2024 earnings released: US$1.49 loss per share (vs US$0.98 loss in 2Q 2023)

Insufficient new directors

CRISPR Therapeutics Announces Executive Changes

First quarter 2024 earnings released: US$1.43 loss per share (vs US$0.67 loss in 1Q 2023)

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach

Now 23% undervalued

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

Full year 2023 earnings released: US$1.94 loss per share (vs US$8.36 loss in FY 2022)

New minor risk - Shareholder dilution

CRISPR Therapeutics AG has filed a Follow-on Equity Offering in the amount of $279.999863 million.

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ for the Treatment of Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$2.24 loss in 3Q 2022)

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$2.40 loss in 2Q 2022)

Insufficient new directors

New minor risk - Shareholder dilution

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

First quarter 2023 earnings released: US$0.67 loss per share (vs US$2.33 loss in 1Q 2022)

CRISPR Therapeutics Appoints Alex Harding, M.D., M.B.A., as Head of Business Development, Effective January 5, 2023

CRISPR Therapeutics AG Provides Update on Its Ongoing Phase 1 Carbon(Tm) Trial of Ctx110(R)

CRISPR Therapeutics Announces Executive Changes

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Second quarter 2022 earnings released: US$2.40 loss per share (vs US$10.01 profit in 2Q 2021)

Investor sentiment improved over the past week

CRISPR Therapeutics AG Elects Maria Fardis as Board Member

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

Investor sentiment improved over the past week

Investor sentiment improved over the past week

CRISPR Therapeutics AG Announces the Appointment of Phuong Khanh Morrow as Chief Medical Officer, Effective May 23, 2022

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

First quarter 2022 earnings released: US$2.33 loss per share (vs US$1.51 loss in 1Q 2021)

CRISPR Therapeutics Proposes Appointment of Maria Fardis to the Board of Directors

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media